The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind,...

Area of Science:

• Rheumatology
• Immunology
• Clinical Trials

Background:

• Patients with non-severe ANCA-associated vasculitis (AAV) face significant side effects from current immunosuppressive treatments.
• There is a critical need for safer and more effective therapeutic options for AAV management.
• Hydroxychloroquine is being investigated for its potential benefits in autoimmune conditions like AAV, drawing parallels with its use in systemic lupus erythematosus.

Purpose of the Study:

• To evaluate the efficacy of hydroxychloroquine as a treatment for non-severe ANCA-associated vasculitis (AAV).
• To assess if hydroxychloroquine can serve as a safer alternative to conventional immunosuppressive therapies, potentially reducing the need for drugs like prednisolone.
• To explore the impact of hydroxychloroquine on disease activity, flares, and remission rates in AAV patients.

Main Methods:

• A double-blind, placebo-controlled, multicentre trial involving 76 patients randomized to receive either hydroxychloroquine or a placebo for 52 weeks, alongside standard care.
• Utilizing a phase II selection design to determine efficacy, with prednisolone dosage and Birmingham Vasculitis Activity Score (BVAS) as primary measures of disease activity.
• Secondary outcome measures include monitoring disease flares and time to achieve remission.

Main Results:

• The trial is designed to determine the efficacy of hydroxychloroquine in treating AAV.
• Results will indicate whether hydroxychloroquine can effectively manage disease activity compared to placebo.
• Data on disease flares and remission rates will be collected to further assess treatment effectiveness.

Conclusions:

• Hydroxychloroquine presents a potential therapeutic option for AAV patients, offering a potentially safer and more tolerable alternative to current treatments.
• Successful outcomes could lead to a reduced requirement for immunosuppressive drugs such as prednisolone, thereby improving patient quality of life.
• This approach may offer cost savings for healthcare systems like the NHS due to hydroxychloroquine's lower cost and improved safety profile.